Orion Biotechnology Canada report that IND- enabling studies evaluating the safety of their OB-002H microbicide gel have shown an excellent mucosal safety profile

OTTAWA, Jan. 29, 2019 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced preclinical data evaluating the safety of OB-002H (5P12-RANTES) which is being developed as a topical microbicide for HIV prevention. We have previously shown that 5P12- RANTES was able to completely prevent SHIV infection in a rhesus … Read moreOrion Biotechnology Canada report that IND- enabling studies evaluating the safety of their OB-002H microbicide gel have shown an excellent mucosal safety profile

Orion Biotechnology Reports Positive Results for Colorectal Cancer in Preclinical Study

Ottawa, Canada [January 15, 2019]:    Orion Biotechnology Canada Ltd., a developer of novel medical treatments,  today announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O (5P12-RANTES) in colorectal cancer. BALB/c mice were inoculated subcutaneously with the CT-26 colorectal cancer cell line. Three days after inoculation intraperitoneal treatment was started … Read moreOrion Biotechnology Reports Positive Results for Colorectal Cancer in Preclinical Study

contact us

Leave  us a message and we will try to respond by the next business day

ORION Logo Pantone(375x133)

Our Headquarters

343 Preston Street

11th floor,

Ottawa, ON K1S 1N4

CANADA

info@orionbiotechnology.com

contact us

Leave  us a message and we will try to respond by the next business day

ORION Logo Pantone(375x133)

Our Headquarters

343 Preston Street

11th floor,

Ottawa, ON K1S 1N4

CANADA

info@orionbiotechnology.com